NextCure Inc

NXTC

Company Profile

  • Business description

    NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

  • Contact

    9000 Virginia Manor Road
    Suite 200
    BeltsvilleMD20705
    USA

    T: +1 240 399-4900

    https://www.nextcure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    40

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,008.00157.40-1.72%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,578.65175.19-0.74%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,956.67705.35-1.18%
NZX 50 Index14,350.6846.910.33%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,892.00152.70-1.69%
SSE Composite Index3,591.8910.68-0.30%

Market Movers